CROSSOVER TRIAL COMPARING THE ANTI-DEPRESSANT EFFECTS OF AMINEPTINE AND MAPROTILINE

被引:12
|
作者
BORNSTEIN, S
机构
[1] Hôpital Psychiatrique, Maison Blanche, Neuilly-sur-Marne
关键词
Amineptine; Antidepressive Agents; Depression; Maprotiline;
D O I
10.1185/03007997909109406
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A double-blind controlled, cross-over trial was carried out in 70 depressed patients to compare the effectiveness and tolerability of amineptine with that of maprotiline. Patients were allocated at random to receive treatment with either 150 mg amineptine or 75 mg maprotiline daily for 6 weeks before being treated for a further 6 weeks with the alternative drug. Comparison of the response to treatment at the end of each period showed that amineptine was significantly better than maprotiline, and this was particularly marked in the 46 patients with exogenous depression where an effect was usually evident within 3 to 5 days. Only 6 patients in this group failed to show a response to amineptine compared with 19 to maprotiline. Both drugs appeared to be equally effective overall in patients with endogenous depression, although when amineptine was given as the second treatment there was an improvement in retardation. Few side-effects were reported during either treatment period. © 1979 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 50 条
  • [1] DOUBLE-BLIND CLINICAL-TRIAL OF THE ANTI-DEPRESSANT ACTION OF AMINEPTINE
    VANAMERONGEN, P
    CURRENT MEDICAL RESEARCH AND OPINION, 1979, 6 (02) : 93 - 100
  • [2] Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review
    de Oliveira, Marcos Roberto
    Chenet, Aline Lukasievicz
    Duarte, Adriane Ribeiro
    Scaini, Giselli
    Quevedo, Joao
    MOLECULAR NEUROBIOLOGY, 2018, 55 (06) : 4543 - 4559
  • [3] Molecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review
    Marcos Roberto de Oliveira
    Aline Lukasievicz Chenet
    Adriane Ribeiro Duarte
    Giselli Scaini
    João Quevedo
    Molecular Neurobiology, 2018, 55 : 4543 - 4559
  • [4] ANTI-DEPRESSANT POTENTIAL OF MUSIC THERAPY
    Arya, Ashwani
    Parle, Milind
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2010, 1 (03): : 61 - 68
  • [5] Phytochemistry and pharmacology of anti-depressant medicinal plants: A review
    Martins, Jeanette
    Brijesh, S.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 : 343 - 365
  • [6] Anti-Depressant Treatment History as a Predictor of Response to Scopolamine
    Brockmeyer, Jessica S.
    Zarate, Carlos A.
    Luckenbaugh, David A.
    Rasimas, Joseph J.
    Mathews, Daniel C.
    Ionescu, Dawn F.
    Niciu, Mark J.
    Richards, Erica M.
    Furey, Maura L.
    BIOLOGICAL PSYCHIATRY, 2013, 73 (09) : 158S - 158S
  • [7] TRYPTOPHAN ANTI-DEPRESSANT PHYSIOLOGICAL SEDATIVE - FACT OR FANCY
    COOPER, AJ
    PSYCHOPHARMACOLOGY, 1979, 61 (01) : 97 - 102
  • [8] COMPARATIVE ANTI-DEPRESSANT VALUE OF LOFEPRAMINE AND AMITRIPTYLINE - RESULTS OF A CONTROLLED TRIAL WITH COMMENTS ON THE SCALES USED
    MCCLELLAND, HA
    KERR, TA
    STEPHENS, DA
    HOWELL, RW
    ACTA PSYCHIATRICA SCANDINAVICA, 1979, 60 (02) : 190 - 198
  • [9] The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol
    Yu, Yingcong
    Wang, Jinhui
    Huang, Xianfeng
    PHARMACEUTICAL BIOLOGY, 2021, 59 (01) : 418 - 423
  • [10] Update to the study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment depressive relapse/recurrence: the PREVENT trial
    Kuyken, Willem
    Byford, Sarah
    Byng, Richard
    Dalgleish, Tim
    Lewis, Glyn
    Taylor, Rod
    Watkins, Edward R.
    Hayes, Rachel
    Lanham, Paul
    Kessler, David
    Morant, Nicola
    Evans, Alison
    TRIALS, 2014, 15